Toward Telemonitoring in Immune-Mediated Inflammatory Diseases: Protocol for a Mixed Attention Model Study

BackgroundRheumatic and musculoskeletal diseases (RMDs) are chronic diseases that may alternate between asymptomatic periods and flares. These conditions require complex treatments and close monitoring by rheumatologists to mitigate their effects and improve the patient’s qua...

Full description

Bibliographic Details
Main Authors: Marta Novella-Navarro, Jose M Iniesta-Chamorro, Diego Benavent, Javier Bachiller-Corral, Enrique Calvo-Aranda, Helena Borrell, Laura Berbel-Arcobé, Victoria Navarro-Compan, Xabier Michelena, Leticia Lojo-Oliveira, Jaime Arroyo-Palomo, Mariana Diaz-Almiron, Verónica García García, Irene Monjo-Henry, Claudia María Gómez González, Enrique J Gomez, Alejandro Balsa, Chamaida Plasencia-Rodríguez
Format: Article
Language:English
Published: JMIR Publications 2024-04-01
Series:JMIR Research Protocols
Online Access:https://www.researchprotocols.org/2024/1/e55829
_version_ 1827276517689786368
author Marta Novella-Navarro
Jose M Iniesta-Chamorro
Diego Benavent
Javier Bachiller-Corral
Enrique Calvo-Aranda
Helena Borrell
Laura Berbel-Arcobé
Victoria Navarro-Compan
Xabier Michelena
Leticia Lojo-Oliveira
Jaime Arroyo-Palomo
Mariana Diaz-Almiron
Verónica García García
Irene Monjo-Henry
Claudia María Gómez González
Enrique J Gomez
Alejandro Balsa
Chamaida Plasencia-Rodríguez
author_facet Marta Novella-Navarro
Jose M Iniesta-Chamorro
Diego Benavent
Javier Bachiller-Corral
Enrique Calvo-Aranda
Helena Borrell
Laura Berbel-Arcobé
Victoria Navarro-Compan
Xabier Michelena
Leticia Lojo-Oliveira
Jaime Arroyo-Palomo
Mariana Diaz-Almiron
Verónica García García
Irene Monjo-Henry
Claudia María Gómez González
Enrique J Gomez
Alejandro Balsa
Chamaida Plasencia-Rodríguez
author_sort Marta Novella-Navarro
collection DOAJ
description BackgroundRheumatic and musculoskeletal diseases (RMDs) are chronic diseases that may alternate between asymptomatic periods and flares. These conditions require complex treatments and close monitoring by rheumatologists to mitigate their effects and improve the patient’s quality of life. Often, delays in outpatient consultations or the patient’s difficulties in keeping appointments make such close follow-up challenging. For this reason, it is very important to have open communication between patients and health professionals. In this context, implementing telemonitoring in the field of rheumatology has great potential, as it can facilitate the close monitoring of patients with RMDs. The use of these tools helps patients self-manage certain aspects of their disease. This could result in fewer visits to emergency departments and consultations, as well as enable better therapeutic compliance and identification of issues that would otherwise go unnoticed. ObjectiveThe main objective of this study is to evaluate the implementation of a hybrid care model called the mixed attention model (MAM) in clinical practice and determine whether its implementation improves clinical outcomes compared to conventional follow-up. MethodsThis is a multicenter prospective observational study involving 360 patients with rheumatoid arthritis (RA) and spondylarthritis (SpA) from 5 Spanish hospitals. The patients will be followed up by the MAM protocol, which is a care model that incorporates a digital tool consisting of a mobile app that patients can use at home and professionals can review asynchronously to detect incidents and follow patients' clinical evolution between face-to-face visits. Another group of patients, whose follow-up will be conducted in accordance with a traditional face-to-face care model, will be assessed as the control group. Sociodemographic characteristics, treatments, laboratory parameters, assessment of tender and swollen joints, visual analog scale for pain, and electronic patient-reported outcome (ePRO) reports will be collected for all participants. In the MAM group, these items will be self-assessed via both the mobile app and during face-to-face visits with the rheumatologist, who will do the same for patients included in the traditional care model. The patients will be able to report any incidence related to their disease or treatment through the mobile app. ResultsParticipant recruitment began in March 2024 and will continue until December 2024. The follow-up period will be extended by 12 months for all patients. Data collection and analysis are scheduled for completion in December 2025. ConclusionsThis paper aims to provide a detailed description of the development and implementation of a digital solution, specifically an MAM. The goal is to achieve significant economic and psychosocial impact within our health care system by enhancing control over RMDs. Trial RegistrationClinicalTrials.gov NCT06273306; https://clinicaltrials.gov/ct2/show/NCT06273306 International Registered Report Identifier (IRRID)PRR1-10.2196/55829
first_indexed 2024-04-24T06:49:01Z
format Article
id doaj.art-931b30faa2aa4dce80bbbefbdc9c5811
institution Directory Open Access Journal
issn 1929-0748
language English
last_indexed 2024-04-24T06:49:01Z
publishDate 2024-04-01
publisher JMIR Publications
record_format Article
series JMIR Research Protocols
spelling doaj.art-931b30faa2aa4dce80bbbefbdc9c58112024-04-22T13:15:50ZengJMIR PublicationsJMIR Research Protocols1929-07482024-04-0113e5582910.2196/55829Toward Telemonitoring in Immune-Mediated Inflammatory Diseases: Protocol for a Mixed Attention Model StudyMarta Novella-Navarrohttps://orcid.org/0000-0002-2200-0859Jose M Iniesta-Chamorrohttps://orcid.org/0000-0002-9496-0293Diego Benaventhttps://orcid.org/0000-0001-9119-5330Javier Bachiller-Corralhttps://orcid.org/0000-0001-8954-209XEnrique Calvo-Arandahttps://orcid.org/0000-0002-3095-0969Helena Borrellhttps://orcid.org/0000-0002-9161-3886Laura Berbel-Arcobéhttps://orcid.org/0000-0003-3373-7503Victoria Navarro-Companhttps://orcid.org/0000-0002-4527-852XXabier Michelenahttps://orcid.org/0000-0002-5352-919XLeticia Lojo-Oliveirahttps://orcid.org/0000-0002-8809-5942Jaime Arroyo-Palomohttps://orcid.org/0000-0002-6954-532XMariana Diaz-Almironhttps://orcid.org/0000-0003-1832-2203Verónica García Garcíahttps://orcid.org/0000-0003-0126-0229Irene Monjo-Henryhttps://orcid.org/0000-0002-3252-8016Claudia María Gómez Gonzálezhttps://orcid.org/0009-0002-8278-8251Enrique J Gomezhttps://orcid.org/0000-0001-6998-1407Alejandro Balsahttps://orcid.org/0000-0001-8070-7062Chamaida Plasencia-Rodríguezhttps://orcid.org/0000-0003-3503-9047 BackgroundRheumatic and musculoskeletal diseases (RMDs) are chronic diseases that may alternate between asymptomatic periods and flares. These conditions require complex treatments and close monitoring by rheumatologists to mitigate their effects and improve the patient’s quality of life. Often, delays in outpatient consultations or the patient’s difficulties in keeping appointments make such close follow-up challenging. For this reason, it is very important to have open communication between patients and health professionals. In this context, implementing telemonitoring in the field of rheumatology has great potential, as it can facilitate the close monitoring of patients with RMDs. The use of these tools helps patients self-manage certain aspects of their disease. This could result in fewer visits to emergency departments and consultations, as well as enable better therapeutic compliance and identification of issues that would otherwise go unnoticed. ObjectiveThe main objective of this study is to evaluate the implementation of a hybrid care model called the mixed attention model (MAM) in clinical practice and determine whether its implementation improves clinical outcomes compared to conventional follow-up. MethodsThis is a multicenter prospective observational study involving 360 patients with rheumatoid arthritis (RA) and spondylarthritis (SpA) from 5 Spanish hospitals. The patients will be followed up by the MAM protocol, which is a care model that incorporates a digital tool consisting of a mobile app that patients can use at home and professionals can review asynchronously to detect incidents and follow patients' clinical evolution between face-to-face visits. Another group of patients, whose follow-up will be conducted in accordance with a traditional face-to-face care model, will be assessed as the control group. Sociodemographic characteristics, treatments, laboratory parameters, assessment of tender and swollen joints, visual analog scale for pain, and electronic patient-reported outcome (ePRO) reports will be collected for all participants. In the MAM group, these items will be self-assessed via both the mobile app and during face-to-face visits with the rheumatologist, who will do the same for patients included in the traditional care model. The patients will be able to report any incidence related to their disease or treatment through the mobile app. ResultsParticipant recruitment began in March 2024 and will continue until December 2024. The follow-up period will be extended by 12 months for all patients. Data collection and analysis are scheduled for completion in December 2025. ConclusionsThis paper aims to provide a detailed description of the development and implementation of a digital solution, specifically an MAM. The goal is to achieve significant economic and psychosocial impact within our health care system by enhancing control over RMDs. Trial RegistrationClinicalTrials.gov NCT06273306; https://clinicaltrials.gov/ct2/show/NCT06273306 International Registered Report Identifier (IRRID)PRR1-10.2196/55829https://www.researchprotocols.org/2024/1/e55829
spellingShingle Marta Novella-Navarro
Jose M Iniesta-Chamorro
Diego Benavent
Javier Bachiller-Corral
Enrique Calvo-Aranda
Helena Borrell
Laura Berbel-Arcobé
Victoria Navarro-Compan
Xabier Michelena
Leticia Lojo-Oliveira
Jaime Arroyo-Palomo
Mariana Diaz-Almiron
Verónica García García
Irene Monjo-Henry
Claudia María Gómez González
Enrique J Gomez
Alejandro Balsa
Chamaida Plasencia-Rodríguez
Toward Telemonitoring in Immune-Mediated Inflammatory Diseases: Protocol for a Mixed Attention Model Study
JMIR Research Protocols
title Toward Telemonitoring in Immune-Mediated Inflammatory Diseases: Protocol for a Mixed Attention Model Study
title_full Toward Telemonitoring in Immune-Mediated Inflammatory Diseases: Protocol for a Mixed Attention Model Study
title_fullStr Toward Telemonitoring in Immune-Mediated Inflammatory Diseases: Protocol for a Mixed Attention Model Study
title_full_unstemmed Toward Telemonitoring in Immune-Mediated Inflammatory Diseases: Protocol for a Mixed Attention Model Study
title_short Toward Telemonitoring in Immune-Mediated Inflammatory Diseases: Protocol for a Mixed Attention Model Study
title_sort toward telemonitoring in immune mediated inflammatory diseases protocol for a mixed attention model study
url https://www.researchprotocols.org/2024/1/e55829
work_keys_str_mv AT martanovellanavarro towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT joseminiestachamorro towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT diegobenavent towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT javierbachillercorral towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT enriquecalvoaranda towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT helenaborrell towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT lauraberbelarcobe towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT victorianavarrocompan towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT xabiermichelena towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT leticialojooliveira towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT jaimearroyopalomo towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT marianadiazalmiron towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT veronicagarciagarcia towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT irenemonjohenry towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT claudiamariagomezgonzalez towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT enriquejgomez towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT alejandrobalsa towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy
AT chamaidaplasenciarodriguez towardtelemonitoringinimmunemediatedinflammatorydiseasesprotocolforamixedattentionmodelstudy